Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
UCB
Biotech
UCB inks $2B Candid buyout to join Gilead in autoimmune field
UCB hijacked Candid's planned reverse merger with Rallybio to challenge Gilead for an emerging opportunity for T-cell engagers.
Nick Paul Taylor
May 4, 2026 7:46am
UCB strikes $1.15B deal for cell therapy biotech Neurona
Apr 17, 2026 1:55pm
UCB enters TCE space with $1.1B deal for autoimmune candidate
Mar 4, 2026 8:20am
Fierce Pharma
FDA's response letter salvo sheds light on drug refusal process
Jul 11, 2025 10:15am
UCB-Novartis Parkinson's asset fails to improve symptoms in ph. 2
Dec 16, 2024 3:19pm
UCB's tau drug flunks Alzheimer's trial days after Roche's exit
Nov 1, 2024 6:01am
